Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer - PubMed
3 hours ago
- #Tumor-Infiltrating Lymphocytes
- #PD-1 Blockade
- #Bladder Cancer
- Tumor-infiltrating lymphocytes (TIL) show strong anti-tumor effects in bladder cancer.
- Combining TIL therapy with PD-1 blockade (Nivolumab) enhances tumor suppression significantly.
- TIL were successfully expanded from bladder cancer samples, predominantly CD8+ cytotoxic T cells.
- Single-cell RNA sequencing revealed enriched cytotoxic effector clones in expanded TIL.
- Patient-derived organoids (PDO) provided a relevant ex vivo platform for evaluating TIL efficacy.
- TIL combined with Nivolumab achieved near-complete tumor suppression in xenograft models.
- The study supports clinical translation of TIL therapy combined with PD-1 blockade for bladder cancer.